Browse the evidence

Lower educational attainment is associated with higher prevalence of hypertension and diabetes, although this association becomes less pronounced after adjusting for other socioeconomic and demographic variables.

Education level is linked to health outcomes, with less education correlating with higher rates of hypertension and diabetes. Public health efforts should focus on providing accessible, easy-to-understand health information and care for individuals with lower educational attainment to reduce these disparities.

Higher levels of the satiety hormone GLP-1 are associated with lower salt taste preference specifically following a low-fat diet.

When eating a low-fat diet, higher levels of the gut hormone GLP-1 are associated with a lower preference for salty foods. This suggests that GLP-1 may play a role in modulating salt taste preferences specifically in the context of low-fat eating.

Obesity pathogenesis is driven by a complex network of 802 core genetic risk genes that function through integrated neurological (appetite regulation, synaptic signaling) and metabolic (lipid/glucose homeostasis) pathways.

Obesity is not just a lifestyle choice; it is heavily influenced by your genetics. If you have a family history of obesity, your body may regulate appetite and metabolism differently. This doesn't mean you can't lose weight, but it means you may need more targeted strategies, such as medical interventions that address specific hormonal pathways (like GLP-1 or MC4R agonists), rather than relying on standard diet advice alone.

Obesity-risk genes are highly expressed in specific cell types: hypothalamic neurons (regulating appetite), pancreatic beta-cells (regulating insulin), adipocytes (lipid homeostasis), and hepatocytes (lipid metabolism).

Obesity affects multiple organs. Your brain (hypothalamus) controls hunger, your pancreas controls insulin, your fat cells store energy, and your liver processes fats. Effective treatment often needs to address these specific tissues, which is why drugs like GLP-1 agonists (which act on the brain and pancreas) are effective.

Ultra-processed foods drive obesity primarily through rapid digestion of carbohydrates leading to metabolic swings and hunger, not through hyper-palatability or tastiness.

Focus on the metabolic impact of food processing rather than just taste. Choose minimally processed foods where the food matrix slows digestion (like whole fruits vs. sugar, or wheat berries vs. white bread). This helps stabilize blood glucose and insulin, reducing the hunger signals that drive overconsumption, regardless of how 'tasty' the food is.

A multidisciplinary care model involving plastic surgeons, bariatric specialists, dieticians, and mental health providers is essential for optimizing safety and outcomes in body contouring surgery for massive weight loss patients.

If you are considering body contouring after significant weight loss, ensure your care team includes not just a surgeon, but also a dietitian to check for nutrient deficiencies, a mental health professional to manage expectations, and a primary care doctor to manage conditions like diabetes. This coordinated approach minimizes complications and improves long-term satisfaction.

GLP-1 receptor agonists are an acceptable adjunct to progestin therapy for fertility preservation in young patients with endometrial cancer or atypical hyperplasia, provided they are framed as medically indicated treatment for cancer and fertility rather than cosmetic weight loss.

If you are a young woman with endometrial cancer or atypical hyperplasia and want to preserve fertility, GLP-1 medications like Semaglutide or Tirzepatide can be a helpful tool alongside progestin therapy. However, you must have a clear, honest conversation with your doctor about the costs, potential side effects, and a plan to keep the weight off after stopping the drug. Framing the medication as a medical treatment for your cancer and fertility, rather than just for weight loss, can help you feel more comfortable and less stigmatized.

Combining obesity management medications (OMM) with metabolic bariatric surgery (MBS) or endoscopic procedures is an inevitable and necessary component of future personalized obesity care, though optimal protocols are currently undefined.

Future obesity care will likely involve combining medications (like GLP-1s) with surgery or endoscopy. This combination is becoming standard to manage weight regain or suboptimal responses, though specific dosing and timing protocols are still being researched.

Post-bariatric surgery weight regain (affecting 15-20% of patients) can be managed with endoscopic interventions or OMM, but optimal dosing and scheduling for these combination therapies remain undefined.

If you regain weight after surgery (affecting 15-20% of patients), you are not out of options. Endoscopic procedures or adding back medications like GLP-1s can help, but doctors currently lack clear guidelines on the best doses and schedules for this specific scenario.

In obese individuals, a combined metabolic index of insulin (INS) and free fatty acids (FFAs) effectively predicts the presence of subclinical left ventricular hypertrophy (LVH), serving as a practical prescreen for early cardiac remodeling risk.

If you are obese, standard blood work might miss early heart strain. Ask your doctor about checking insulin and free fatty acids alongside standard lipids. This combination can flag heart thickening (LVH) before your heart's pumping ability drops, allowing for earlier lifestyle or medical intervention.

Triglycerides (TG) are the most robust independent predictor of the continuous burden of left ventricular mass (LVM) in obesity, whereas insulin and FFAs predict the threshold transition to hypertrophy.

High triglycerides are a strong indicator of increasing heart muscle mass in obesity. Monitoring TG levels can help track the gradual structural load on the heart, even if blood pressure and pumping function seem normal.

High daily consumption of carbohydrates (>60% of total energy) and simple sugars (>10% of total energy) is associated with a statistically significant increase in breast cancer risk.

To potentially lower breast cancer risk, aim to keep carbohydrate intake below 60% of your total daily energy and ensure simple sugars (added sugars) do not exceed 10% of your total energy. Focus on reducing refined sugars and high-glycemic carbohydrates, as high intake of these is linked to a significantly higher risk of developing breast cancer in this study.

Ketogenic dietary therapies (KDTs) may improve cerebrovascular health and neuroprotection by shifting brain energy metabolism from glucose to ketone bodies (specifically β-hydroxybutyrate), reducing oxidative stress, and modulating inflammatory signaling, though current human evidence is limited and heterogeneous.

If you have cognitive concerns or are aging, a ketogenic diet might offer neuroprotective benefits by shifting your brain's fuel source to ketones, which may reduce inflammation and oxidative stress. However, current human evidence is not strong enough to recommend it broadly. If you try it, consider less restrictive versions like the Modified Atkins Diet for better long-term adherence, and be aware that benefits may take weeks to manifest as your body adapts (keto-adaptation).

The weight loss benefit of tirzepatide over semaglutide is significantly attenuated or absent in patients with type 2 diabetes compared to those without diabetes.

For patients with diabetes, the weight loss advantage of tirzepatide over semaglutide seen in non-diabetics may not be present. Consult your doctor to manage expectations regarding weight loss if you have diabetes.

Skeletal muscle releases myokines (such as Irisin and Myostatin) during exercise, which mediate interorgan crosstalk to improve metabolic health, regulate adipose tissue, and protect against cardiovascular disease.

Understand that exercise is a systemic therapy. When you move, your muscles release signals that improve the health of your heart, brain, and fat tissue, not just the muscles themselves.

Traditional Asian dietary practices, including the consumption of ulam, probiotics from fermented foods, and herbs like curcumin and green tea, reduce dementia risk through anti-inflammatory and gut-brain axis mechanisms.

Incorporate more fermented foods (yogurt, kimchi, miso), herbs like turmeric and green tea, and leafy vegetables into your diet. These support gut health and reduce inflammation, which benefits brain health.

GLP-1 RAs show therapeutic potential in neurological disorders, including Alzheimer's and Parkinson's disease, by reducing amyloid-β/tau pathology, neuroinflammation, and promoting neuronal survival.

GLP-1 medications are being studied for Alzheimer's and Parkinson's disease. Some trials show promise in slowing brain volume loss, but results are mixed. They are not yet a standard treatment for these conditions. Consult a neurologist if interested in clinical trials.

Chronic consumption of monosodium glutamate (MSG) is associated with increased risk of obesity and weight gain, primarily through mechanisms involving hypothalamic damage, leptin resistance, and altered gut microbiota.

While MSG is legally safe, emerging research suggests high chronic intake, especially from processed foods with hidden MSG, may disrupt appetite regulation and contribute to weight gain. To mitigate potential risk, prioritize whole foods and check labels for hidden sources like hydrolyzed protein or yeast extract.

Specific additives found in UPFs, such as carrageenan and endocrine-disrupting chemicals like Bisphenol-A (BPA) and acrylamide, contribute to T2DM risk through mechanisms involving insulin resistance, inflammation, and gut microbiota alteration.

Be aware that certain additives (carrageenan, specific emulsifiers) and packaging-derived chemicals (BPA, phthalates) in UPFs may promote insulin resistance and inflammation. Reducing intake of products containing these specific ingredients, especially sugary beverages and processed meats, may lower T2DM risk.

Tirzepatide may allow some patients with moderate OSA (AHI 15-30) who are asymptomatic (except for snoring) to discontinue CPAP, as the benefit of CPAP in this subgroup is unclear.

If you have moderate OSA and are not sleepy (only snoring), ask your doctor if you can try tirzepatide alone. Since CPAP's benefit in asymptomatic moderate OSA is unclear, tirzepatide might resolve your OPA without the need for a machine. This requires monitoring and may not be suitable for everyone.

GLP-1 receptor agonists may have disease-modifying effects on osteoarthritis and osteoporosis by reducing inflammation and promoting bone formation.

If you have joint pain or weak bones, ask your doctor if your GLP-1 medication might offer extra protection. While weight loss is the main benefit, these drugs may also reduce inflammation in joints and help maintain bone density.

GLP-1 receptor agonists (GLP-1RAs) reduce the risk of hepatic decompensation events in patients with type 2 diabetes and compensated cirrhosis compared to DPP4 inhibitors and sulfonylureas.

If you have type 2 diabetes and compensated cirrhosis, GLP-1 receptor agonists may help reduce your risk of serious liver complications like fluid buildup or bleeding compared to other common diabetes medications. Discuss the benefits and risks with your doctor.

GLP-1 receptor agonists (GLP-1 RAs) reduce alcohol consumption and craving in patients with Alcohol Use Disorder (AUD) by modulating the mesolimbic dopamine reward pathway.

If you have AUD, especially if you also have obesity or Type 2 Diabetes, GLP-1 medications (like Semaglutide) may help reduce your alcohol intake and cravings by affecting brain reward pathways. This is an emerging off-label use, so discuss it with your doctor, particularly if standard treatments have failed or caused side effects.

GLP-1 receptor agonists (GLP-1 RAs) reduce systemic and intestinal inflammation in Inflammatory Bowel Disease (IBD) by modulating immune cell signaling, enhancing the intestinal epithelial barrier, and improving gut microbiota composition.

If you have IBD and are considering GLP-1 medications (like Semaglutide or Liraglutide) for weight loss or diabetes, current evidence suggests they may actually help your gut health by reducing inflammation and lowering the risk of surgery. Start with a low dose and titrate slowly to manage nausea. Monitor your symptoms, but know that studies show these drugs do not increase the risk of IBD flares or hospitalizations compared to other diabetes medications. If you are underweight, discuss this carefully with your doctor, as the primary benefit in obese IBD patients is well-documented.